Using the data from the cross-sectional Medical Expenditure Panel Survey from January 2006 through December 2015, researchers found that one in four low-income families with a member with ASCVD experience a high financial burden from the out-of-pocket healthcare costs associated with treating the chronic condition.
Musculoskeletal disorders impose a substantial economic burden on American society, but few studies have examined the economic benefits associated with treating such disorders.
The caveat associated with treating smaller numbers of affected individuals more frequently is that if scabies burden is initially high, it may take an extended period of time before lower prevalence rates are achieved.
The costs associated with treating these ills are enormous.
In this sense, the clinical outcomes related to frailty should be treated to prevent the socioeconomic burden associated with this condition.
The lack of any clinical protocol to treat type II patients with GD and the financial burden associated with ERT make a unifying systemic treatment with perinatally administered AAV9-mediated gene therapy an essential and economically viable solution.
When choosing the most efficient therapy for treating pediatric AR, it is possible to impact on the significant morbidity and economic burden associated with the disease.
Given the increase in comorbidity burden associated with CTS patients in the baseline and study comparison, there may be evidence that these patients are not appropriately treated.
Cancer treatments, including chemotherapy, major surgery, and other long-term treatments, make cancer the most expensive disease to treat, and the cost continues to increase; in addition to the economic burden, the social burden associated with cancer is also huge.
Treating tobacco dependence, therefore, is likely to have benefits for controlling tuberculosis in addition to reducing the non-communicable disease burden associated with smoking.
